|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM22 |
Gene summary for TRIM22 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM22 | Gene ID | 10346 |
| Gene name | tripartite motif containing 22 | |
| Gene Alias | GPSTAF50 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | B4DQS5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10346 | TRIM22 | LZE5T | Human | Esophagus | ESCC | 3.11e-02 | 2.76e-01 | 0.0514 |
| 10346 | TRIM22 | LZE8T | Human | Esophagus | ESCC | 4.44e-06 | 5.41e-02 | 0.067 |
| 10346 | TRIM22 | LZE20T | Human | Esophagus | ESCC | 4.53e-04 | 7.90e-02 | 0.0662 |
| 10346 | TRIM22 | LZE24T | Human | Esophagus | ESCC | 6.53e-16 | 5.34e-01 | 0.0596 |
| 10346 | TRIM22 | P2T-E | Human | Esophagus | ESCC | 6.48e-31 | 5.86e-01 | 0.1177 |
| 10346 | TRIM22 | P4T-E | Human | Esophagus | ESCC | 3.91e-02 | -1.27e-01 | 0.1323 |
| 10346 | TRIM22 | P5T-E | Human | Esophagus | ESCC | 2.29e-04 | 1.63e-02 | 0.1327 |
| 10346 | TRIM22 | P8T-E | Human | Esophagus | ESCC | 1.21e-17 | 1.96e-01 | 0.0889 |
| 10346 | TRIM22 | P9T-E | Human | Esophagus | ESCC | 1.01e-30 | 8.03e-01 | 0.1131 |
| 10346 | TRIM22 | P10T-E | Human | Esophagus | ESCC | 2.16e-03 | -2.10e-01 | 0.116 |
| 10346 | TRIM22 | P11T-E | Human | Esophagus | ESCC | 2.13e-26 | 1.20e+00 | 0.1426 |
| 10346 | TRIM22 | P12T-E | Human | Esophagus | ESCC | 4.85e-06 | -1.07e-01 | 0.1122 |
| 10346 | TRIM22 | P16T-E | Human | Esophagus | ESCC | 1.46e-04 | -1.24e-01 | 0.1153 |
| 10346 | TRIM22 | P17T-E | Human | Esophagus | ESCC | 1.41e-15 | 7.74e-01 | 0.1278 |
| 10346 | TRIM22 | P21T-E | Human | Esophagus | ESCC | 1.43e-05 | 2.67e-01 | 0.1617 |
| 10346 | TRIM22 | P22T-E | Human | Esophagus | ESCC | 1.53e-09 | -4.10e-02 | 0.1236 |
| 10346 | TRIM22 | P23T-E | Human | Esophagus | ESCC | 4.47e-07 | 2.58e-01 | 0.108 |
| 10346 | TRIM22 | P24T-E | Human | Esophagus | ESCC | 1.13e-26 | 7.57e-01 | 0.1287 |
| 10346 | TRIM22 | P26T-E | Human | Esophagus | ESCC | 2.48e-04 | -1.51e-01 | 0.1276 |
| 10346 | TRIM22 | P27T-E | Human | Esophagus | ESCC | 1.89e-14 | 7.27e-02 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961522 | Skin | cSCC | response to virus | 152/4864 | 367/18723 | 5.88e-11 | 2.75e-09 | 152 |
| GO:004440328 | Skin | cSCC | biological process involved in symbiotic interaction | 126/4864 | 290/18723 | 6.39e-11 | 2.97e-09 | 126 |
| GO:000020924 | Skin | cSCC | protein polyubiquitination | 103/4864 | 236/18723 | 2.57e-09 | 9.09e-08 | 103 |
| GO:005170129 | Skin | cSCC | biological process involved in interaction with host | 91/4864 | 203/18723 | 4.30e-09 | 1.45e-07 | 91 |
| GO:0050792112 | Skin | cSCC | regulation of viral process | 77/4864 | 164/18723 | 5.38e-09 | 1.78e-07 | 77 |
| GO:0043123110 | Skin | cSCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 84/4864 | 186/18723 | 1.09e-08 | 3.40e-07 | 84 |
| GO:000724925 | Skin | cSCC | I-kappaB kinase/NF-kappaB signaling | 116/4864 | 281/18723 | 1.33e-08 | 4.08e-07 | 116 |
| GO:004312225 | Skin | cSCC | regulation of I-kappaB kinase/NF-kappaB signaling | 105/4864 | 249/18723 | 1.70e-08 | 5.09e-07 | 105 |
| GO:001050619 | Skin | cSCC | regulation of autophagy | 127/4864 | 317/18723 | 2.36e-08 | 6.71e-07 | 127 |
| GO:1903900112 | Skin | cSCC | regulation of viral life cycle | 68/4864 | 148/18723 | 1.17e-07 | 2.77e-06 | 68 |
| GO:00516076 | Skin | cSCC | defense response to virus | 107/4864 | 265/18723 | 1.84e-07 | 4.02e-06 | 107 |
| GO:01405466 | Skin | cSCC | defense response to symbiont | 107/4864 | 265/18723 | 1.84e-07 | 4.02e-06 | 107 |
| GO:005212629 | Skin | cSCC | movement in host environment | 76/4864 | 175/18723 | 3.81e-07 | 7.55e-06 | 76 |
| GO:004440929 | Skin | cSCC | entry into host | 59/4864 | 151/18723 | 2.75e-04 | 2.22e-03 | 59 |
| GO:004671829 | Skin | cSCC | viral entry into host cell | 56/4864 | 144/18723 | 4.46e-04 | 3.42e-03 | 56 |
| GO:004390325 | Skin | cSCC | regulation of biological process involved in symbiotic interaction | 31/4864 | 72/18723 | 1.21e-03 | 7.86e-03 | 31 |
| GO:005109214 | Skin | cSCC | positive regulation of NF-kappaB transcription factor activity | 55/4864 | 152/18723 | 3.40e-03 | 1.84e-02 | 55 |
| GO:00105089 | Skin | cSCC | positive regulation of autophagy | 45/4864 | 124/18723 | 7.08e-03 | 3.40e-02 | 45 |
| GO:0009896113 | Thyroid | PTC | positive regulation of catabolic process | 278/5968 | 492/18723 | 3.35e-30 | 2.64e-27 | 278 |
| GO:0031331113 | Thyroid | PTC | positive regulation of cellular catabolic process | 249/5968 | 427/18723 | 5.28e-30 | 3.58e-27 | 249 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM22 | SNV | Missense_Mutation | c.87T>A | p.Asp29Glu | p.D29E | Q8IYM9 | protein_coding | deleterious(0.04) | possibly_damaging(0.497) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TRIM22 | SNV | Missense_Mutation | rs775271050 | c.1055N>T | p.Ser352Leu | p.S352L | Q8IYM9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM22 | SNV | Missense_Mutation | rs368256788 | c.1418N>A | p.Arg473His | p.R473H | Q8IYM9 | protein_coding | tolerated(0.55) | benign(0.01) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM22 | SNV | Missense_Mutation | rs372042006 | c.979C>T | p.Arg327Cys | p.R327C | Q8IYM9 | protein_coding | tolerated(0.21) | benign(0) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM22 | SNV | Missense_Mutation | novel | c.179A>G | p.Gln60Arg | p.Q60R | Q8IYM9 | protein_coding | tolerated(1) | possibly_damaging(0.601) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM22 | SNV | Missense_Mutation | c.757N>T | p.Ile253Phe | p.I253F | Q8IYM9 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| TRIM22 | SNV | Missense_Mutation | rs553638122 | c.511G>A | p.Ala171Thr | p.A171T | Q8IYM9 | protein_coding | tolerated(0.13) | benign(0) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| TRIM22 | SNV | Missense_Mutation | c.223G>A | p.Ala75Thr | p.A75T | Q8IYM9 | protein_coding | deleterious(0.04) | benign(0.036) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM22 | SNV | Missense_Mutation | c.1417C>T | p.Arg473Cys | p.R473C | Q8IYM9 | protein_coding | tolerated(0.22) | benign(0.003) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| TRIM22 | SNV | Missense_Mutation | c.1013N>C | p.Asp338Ala | p.D338A | Q8IYM9 | protein_coding | tolerated(0.1) | benign(0.243) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |